MAPT and Alzheimer disease: Interestingly, increases in specific phosphorylated residues of tau have been developed as biomarkers measurable in CSF or plasma from AD patients but are not observed in primary tauopathies, emphasizing that they may more likely reflect Aβ pathology (Zetterberg 2022; Therriault et al. 2023).